Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300

1.

Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM.

Mol Cancer Ther. 2019 Feb;18(2):399-412. doi: 10.1158/1535-7163.MCT-18-0710. Epub 2018 Dec 5.

PMID:
30518672
2.

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.

Kou J, Musich PR, Staal B, Kang L, Qin Y, Yao ZQ, Zhang B, Wu W, Tam A, Huang A, Hao HX, Vande Woude GF, Xie Q.

J Transl Med. 2018 Sep 12;16(1):253. doi: 10.1186/s12967-018-1628-y.

3.

Structural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases.

Pal K, Bandyopadhyay A, Zhou XE, Xu Q, Marciano DP, Brunzelle JS, Yerrum S, Griffin PR, Vande Woude G, Melcher K, Xu HE.

Structure. 2017 Jun 6;25(6):867-877.e3. doi: 10.1016/j.str.2017.04.015. Epub 2017 May 18.

4.

MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection.

Sakamoto N, Tsujimoto H, Takahata R, Cao B, Zhao P, Ito N, Shimazaki H, Ichikura T, Hase K, Vande Woude GF, Shinomiya N.

Cancer Sci. 2017 Mar;108(3):322-330. doi: 10.1111/cas.13146.

5.

Chromosome instability drives phenotypic switching to metastasis.

Gao C, Su Y, Koeman J, Haak E, Dykema K, Essenberg C, Hudson E, Petillo D, Khoo SK, Vande Woude GF.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14793-14798. doi: 10.1073/pnas.1618215113. Epub 2016 Dec 5.

6.

Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET.

Huang F, Ma Z, Pollan S, Yuan X, Swartwood S, Gertych A, Rodriguez M, Mallick J, Bhele S, Guindi M, Dhall D, Walts AE, Bose S, de Peralta Venturina M, Marchevsky AM, Luthringer DJ, Feller SM, Berman B, Freeman MR, Alvord WG, Vande Woude G, Amin MB, Knudsen BS.

J Pathol Clin Res. 2016 Jul 1;2(4):210-222. eCollection 2016 Oct.

7.

Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.

Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K, Marincola FM, Berens ME, Vande Woude GF, Xie Q.

J Transl Med. 2015 Sep 17;13:306. doi: 10.1186/s12967-015-0667-x.

8.

Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation.

Staal B, Williams BO, Beier F, Vande Woude GF, Zhang YW.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2590-5. doi: 10.1073/pnas.1400744111. Epub 2014 Feb 3.

9.

Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy.

Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, Huang A, Schlegel R, Essenburg C, Kang L, Iwaya K, Seki S, Khoo SK, Zhang B, Buonaguro F, Marincola FM, Furge K, Vande Woude GF, Shinomiya N.

Genes Cancer. 2013 Jul;4(7-8):247-60. doi: 10.1177/1947601913501075.

10.

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, Santell L, Zhang YW, Su Y, Kaufman DW, Billeci KL, Mai E, Moffat B, Lim A, Duenas ET, Phillips HS, Xiang H, Young JC, Vande Woude GF, Dennis MS, Reilly DE, Schwall RH, Starovasnik MA, Lazarus RA, Yansura DG.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. doi: 10.1073/pnas.1302725110. Epub 2013 Jul 23.

11.

MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.

Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE, Melnik MK, Vande Woude GF, Graveel CR.

Mol Cancer Res. 2013 Sep;11(9):1112-21. doi: 10.1158/1541-7786.MCR-13-0042. Epub 2013 Jul 3.

12.

MET: a critical player in tumorigenesis and therapeutic target.

Graveel CR, Tolbert D, Vande Woude GF.

Cold Spring Harb Perspect Biol. 2013 Jul 1;5(7). pii: a009209. doi: 10.1101/cshperspect.a009209. Review.

13.

Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.

Zhang YW, Staal B, Essenburg C, Lewis S, Kaufman D, Vande Woude GF.

Mol Cancer Ther. 2013 Aug;12(8):1429-41. doi: 10.1158/1535-7163.MCT-13-0016. Epub 2013 May 29.

14.

RTK inhibition: looking for the right pathways toward a miracle.

Xie Q, Vande Woude GF, Berens ME.

Future Oncol. 2012 Nov;8(11):1397-400. doi: 10.2217/fon.12.130.

PMID:
23148613
15.

Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.

Nickoloff BJ, Vande Woude G.

Pigment Cell Melanoma Res. 2012 Nov;25(6):758-61. doi: 10.1111/pcmr.12020. No abstract available.

PMID:
22974232
16.

Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.

Zhang YW, Staal B, Dykema KJ, Furge KA, Vande Woude GF.

PLoS One. 2012;7(6):e38955. doi: 10.1371/journal.pone.0038955. Epub 2012 Jun 12.

17.

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.

Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT.

Nat Med. 2012 Jul;18(7):1118-22. doi: 10.1038/nm.2819.

18.

Targeting MET in cancer: rationale and progress.

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G.

Nat Rev Cancer. 2012 Jan 24;12(2):89-103. doi: 10.1038/nrc3205. Review. Erratum in: Nat Rev Cancer. 2012 Sep;12(9):637.

PMID:
22270953
19.

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.

Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, Essenburg C, Kaufman DW, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, Vande Woude GF.

Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):570-5. doi: 10.1073/pnas.1119059109. Epub 2011 Dec 27.

20.

Proinvasion metastasis drivers in early-stage melanoma are oncogenes.

Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, Cameron LA, Perry SR, Zeid R, Feinberg T, Kim M, Vande Woude G, Granter SR, Bosenberg M, Chu GC, DePinho RA, Rimm DL, Chin L.

Cancer Cell. 2011 Jul 12;20(1):92-103. doi: 10.1016/j.ccr.2011.05.025.

21.

Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion.

Xie Q, Wondergem R, Shen Y, Cavey G, Ke J, Thompson R, Bradley R, Daugherty-Holtrop J, Xu Y, Chen E, Omar H, Rosen N, Wenkert D, Xu HE, Vande Woude GF.

Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4105-10. doi: 10.1073/pnas.1015181108. Epub 2011 Feb 22. Erratum in: Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5472. Daughtery-Holtrop, Jennifer [corrected to Daugherty-Holtrop, Jennifer].

22.

Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.

Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF.

PLoS One. 2010 Oct 25;5(10):e13586. doi: 10.1371/journal.pone.0013586.

23.

RhoA and RhoC are both required for the ROCK II-dependent promotion of centrosome duplication.

Kanai M, Crowe MS, Zheng Y, Vande Woude GF, Fukasawa K.

Oncogene. 2010 Nov 11;29(45):6040-50. doi: 10.1038/onc.2010.328. Epub 2010 Aug 9.

24.

Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.

Melnik MK, Webb CP, Richardson PJ, Luttenton CR, Campbell AD, Monroe TJ, O'Rourke TJ, Yost KJ, Szczepanek CM, Bassett MR, Truszkowski KJ, Stein P, Van Brocklin MW, Davis AT, Bedolla G, Vande Woude GF, Koo HM.

Mol Cancer Ther. 2010 Aug;9(8):2423-9. doi: 10.1158/1535-7163.MCT-09-0854. Epub 2010 Aug 3.

25.

MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.

Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF.

Cancer Res. 2010 Sep 1;70(17):6880-90. doi: 10.1158/0008-5472.CAN-10-0898. Epub 2010 Jul 19. Erratum in: Cancer Res. 2011 Apr 1;71(7):2804.

26.

Structural basis for agonism and antagonism of hepatocyte growth factor.

Tolbert WD, Daugherty-Holtrop J, Gherardi E, Vande Woude G, Xu HE.

Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13264-9. doi: 10.1073/pnas.1005183107. Epub 2010 Jul 12.

27.

Screening and detection of breast cancer and prostate cancer.

Paneth N, Vande Woude G, Kort E.

JAMA. 2010 Mar 17;303(11):1032-3; author reply 1033-4. doi: 10.1001/jama.2010.274. No abstract available.

PMID:
20233816
28.

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.

Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF.

Mol Cancer Ther. 2009 Oct;8(10):2803-10. doi: 10.1158/1535-7163.MCT-09-0125.

29.

The decline in U.S. cancer mortality in people born since 1925.

Kort EJ, Paneth N, Vande Woude GF.

Cancer Res. 2009 Aug 15;69(16):6500-5. doi: 10.1158/0008-5472.CAN-09-0357.

30.

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12909-14. doi: 10.1073/pnas.0810403106. Epub 2009 Jun 30.

31.

Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease.

Jeong JW, Lee HS, Lee KY, White LD, Broaddus RR, Zhang YW, Vande Woude GF, Giudice LC, Young SL, Lessey BA, Tsai SY, Lydon JP, DeMayo FJ.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8677-82. doi: 10.1073/pnas.0903632106. Epub 2009 May 13.

32.

Met amplification and tumor progression in Cdkn2a-deficient melanocytes.

Vanbrocklin MW, Robinson JP, Whitwam T, Guilbeault AR, Koeman J, Swiatek PJ, Vande Woude GF, Khoury JD, Holmen SL.

Pigment Cell Melanoma Res. 2009 Aug;22(4):454-60. doi: 10.1111/j.1755-148X.2009.00576.x. Epub 2009 Apr 29.

33.

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Eder JP, Vande Woude GF, Boerner SA, LoRusso PM.

Clin Cancer Res. 2009 Apr 1;15(7):2207-14. doi: 10.1158/1078-0432.CCR-08-1306. Epub 2009 Mar 24. Review.

34.

A highly invasive human glioblastoma pre-clinical model for testing therapeutics.

Xie Q, Thompson R, Hardy K, DeCamp L, Berghuis B, Sigler R, Knudsen B, Cottingham S, Zhao P, Dykema K, Cao B, Resau J, Hay R, Vande Woude GF.

J Transl Med. 2008 Dec 3;6:77. doi: 10.1186/1479-5876-6-77.

35.

A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.

Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Vande Woude G, Cao B.

Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):57-67. doi: 10.1097/PAI.0b013e3181816ae2.

36.

Advances in Cancer Research: Centennial Volume. Introduction.

Klein G, Vande Woude GF.

Adv Cancer Res. 2008;100:v-vii. doi: 10.1016/S0065-230X(08)00008-0. No abstract available.

PMID:
18620090
37.

Showering c-MET-dependent cancers with drugs.

Knudsen BS, Vande Woude G.

Curr Opin Genet Dev. 2008 Feb;18(1):87-96. doi: 10.1016/j.gde.2008.02.001. Epub 2008 Apr 9. Review.

PMID:
18406132
38.

The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution.

Rouleau C, Menon K, Boutin P, Guyre C, Yoshida H, Kataoka S, Perricone M, Shankara S, Frankel AE, Duesbery NS, Vande Woude G, Biemann HP, Teicher BA.

Int J Oncol. 2008 Apr;32(4):739-48.

PMID:
18360701
39.

Identification of a met-binding peptide from a phage display library.

Zhao P, Grabinski T, Gao C, Skinner RS, Giambernardi T, Su Y, Hudson E, Resau J, Gross M, Vande Woude GF, Hay R, Cao B.

Clin Cancer Res. 2007 Oct 15;13(20):6049-55.

40.

A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.

Tolbert WD, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, Vande Woude G, Xu HE.

Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14592-7. Epub 2007 Sep 5.

41.

Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.

Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N.

Histopathology. 2007 Jul;51(1):54-62.

PMID:
17593080
42.

Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations.

Gao C, Furge K, Koeman J, Dykema K, Su Y, Cutler ML, Werts A, Haak P, Vande Woude GF.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8995-9000. Epub 2007 May 15.

43.

Mig-6, signal transduction, stress response and cancer.

Zhang YW, Vande Woude GF.

Cell Cycle. 2007 Mar 1;6(5):507-13. Epub 2007 Mar 31. Review.

PMID:
17351343
44.

c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.

Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E.

Cancer Res. 2007 Feb 15;67(4):1670-9.

45.

An alternatively spliced form of Met receptor is tumorigenic.

Lee JH, Gao CF, Lee CC, Kim MD, Vande Woude GF.

Exp Mol Med. 2006 Oct 31;38(5):565-73.

PMID:
17079873
46.

Evidence that MIG-6 is a tumor-suppressor gene.

Zhang YW, Staal B, Su Y, Swiatek P, Zhao P, Cao B, Resau J, Sigler R, Bronson R, Vande Woude GF.

Oncogene. 2007 Jan 11;26(2):269-76. Epub 2006 Jul 3.

PMID:
16819504
47.

In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.

Moshitch-Moshkovitz S, Tsarfaty G, Kaufman DW, Stein GY, Shichrur K, Solomon E, Sigler RH, Resau JH, Vande Woude GF, Tsarfaty I.

Neoplasia. 2006 May;8(5):353-63.

48.

HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met.

Tsarfaty G, Stein GY, Moshitch-Moshkovitz S, Kaufman DW, Cao B, Resau JH, Vande Woude GF, Tsarfaty I.

Neoplasia. 2006 May;8(5):344-52.

49.

BRAF and MEK mutations make a late entrance.

Duesbery N, Vande Woude G.

Sci STKE. 2006 Mar 28;2006(328):pe15.

PMID:
16569817
50.

Structural basis of hepatocyte growth factor/scatter factor and MET signalling.

Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, Svergun DI.

Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4046-51. Epub 2006 Mar 6.

Supplemental Content

Loading ...
Support Center